Print Page   |   Report Abuse   |   Sign In   |   Join UPhA
News & Press: Advocacy

CMS’ Proposed DIR Fee Reform Garners Industry Support

Wednesday, November 28, 2018   (0 Comments)
Share |

The latest effort from the Centers for Medicare and Medicaid Services is garnering industry attention. CMS on Tuesday unveiled a proposed rule, titled “Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses,” which includes provisions focused on direct and indirect remuneration, or DIR fee reform.

The proposed rule is interested, among other things, in transparently pricing drugs and seeks to redefine what constitutes “negotiated prices” under Medicare Part D to mean “the lowest amount a pharmacy could receive as reimbursement” for Part D drugs through its contract with the plan sponsor or intermediary. This would require PBMs and plan sponsors to include the lowest possible reimbursement in their claims processing systems.

It also would add a definition for “price concession” in Part D to include “all forms of discounts and direct or indirect subsidies or rebates that serve to reduce the costs incurred under Part D plans by Part D sponsors.”


Community Search
Sign In